본문 바로가기
KERD
논문KCI 등재

COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis

Xianhua Mao|Wai Kay Seto|Man Fung Yuen|Chiu Hang Mok|Ka Shing Cheung|Ruiqi Zhang|Ivan FN Hung
대한간학회 (The korean Association for the Study of the Liver)|2022.10|Clinical and Molecular Hepatology|제28권 제4호|pp. 890-911

0

조회

0

다운로드

3

인용

0

참고문헌

키워드

COVID-19SARS-CoV-2Chronic hepatitis BNon-alcoholic fatty liver diseaseLiver transplant

초록

Background/Aims: Data of coronavirus disease 2019 (COVID-19) vaccine immunogenicity among chronic liver disease (CLD) and liver transplant (LT) patients are conflicting. We performed meta-analysis to examine vaccine immunogenicity regarding etiology, cirrhosis status, vaccine platform and type of antibody. Methods: We collected data via three databases from inception to February 16, 2022, and reported pooled seroconversion rate, T cell response and safety data after two vaccine doses. Results: Twenty-eight (CLD only: 5; LT only: 18; both: 2; LT with third dose: 3) observational studies of 3,945 patients were included. For CLD patients, seroconversion rate ranged between 84% (95% confidence interval [CI], 76–90%) and 91% (95% CI, 83–95%), based predominantly on neutralizing antibody and anti-spike antibody, respectively. Seroconversion rate was 81% (95% CI, 76–86%) in chronic hepatitis B, 96% (95% CI, 93–97%) in non-alcoholic fatty liver disease, 85% (95% CI, 75–91%) in cirrhosis and 85% (95% CI, 78–90%) in non-cirrhosis, 86% (95% CI, 78–92%) for inactivated vaccine and 89% (95% CI, 71–96%) for mRNA vaccine. The pooled seroconversion rate of anti-spike antibody was 66% (95% CI, 55– 75%) after two doses of mRNA vaccines and 88% (95% CI, 58–98%) after third dose among LT recipients. T cell response rate was 65% (95% CI, 30–89%). Prevalence of adverse events was 27% (95% CI, 18–38%) and 63% (95% CI, 39–82%) among CLD and LT groups, respectively. Conclusions: CLD patients had good humoral response to COVID-19 vaccine, while LT recipients had lower response.

Abstract

Background/Aims: Data of coronavirus disease 2019 (COVID-19) vaccine immunogenicity among chronic liver disease (CLD) and liver transplant (LT) patients are conflicting. We performed meta-analysis to examine vaccine immunogenicity regarding etiology, cirrhosis status, vaccine platform and type of antibody. Methods: We collected data via three databases from inception to February 16, 2022, and reported pooled seroconversion rate, T cell response and safety data after two vaccine doses. Results: Twenty-eight (CLD only: 5; LT only: 18; both: 2; LT with third dose: 3) observational studies of 3,945 patients were included. For CLD patients, seroconversion rate ranged between 84% (95% confidence interval [CI], 76–90%) and 91% (95% CI, 83–95%), based predominantly on neutralizing antibody and anti-spike antibody, respectively. Seroconversion rate was 81% (95% CI, 76–86%) in chronic hepatitis B, 96% (95% CI, 93–97%) in non-alcoholic fatty liver disease, 85% (95% CI, 75–91%) in cirrhosis and 85% (95% CI, 78–90%) in non-cirrhosis, 86% (95% CI, 78–92%) for inactivated vaccine and 89% (95% CI, 71–96%) for mRNA vaccine. The pooled seroconversion rate of anti-spike antibody was 66% (95% CI, 55– 75%) after two doses of mRNA vaccines and 88% (95% CI, 58–98%) after third dose among LT recipients. T cell response rate was 65% (95% CI, 30–89%). Prevalence of adverse events was 27% (95% CI, 18–38%) and 63% (95% CI, 39–82%) among CLD and LT groups, respectively. Conclusions: CLD patients had good humoral response to COVID-19 vaccine, while LT recipients had lower response.

참고문헌 (53)

  1. "COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)"[URL]
  2. Polack FP, "Safety and efficacy of the BNT162b2 mRNA Covid-19vaccine", N Engl J Med, 383, pp.2603~2615 (2020)
  3. Baden LR, "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine", N Engl J Med, 384, pp.403~416 (2021)
  4. Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222)against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
  5. Palacios R, "Double-blind, randomized, placebocontrolled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19(inactivated)vaccine manufactured by sinovac-PROFISCOV : a structured summary of a study protocol for a randomised controlled trial", Trials, 21, pp.853~ (2020)
  6. Xia S, "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV : a randomised, double-blind, placebo-controlled, phase 1", 2 trial, 2021, pp.21, 39~51
  7. Marjot T, "Outcomes following SARS-CoV-2 infection in patients with chronic liver disease : an international registry study", J Hepatol, 74, pp.567~577 (2021)
  8. Bajaj JS, "Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone : multicentre matched cohort", Gut, 70, pp.531~536 (2021)
  9. Bonnel AR, "Immune dysfunction and infections in patients with cirrhosis", Clin Gastroenterol Hepatol, 9, pp.727~738 (2011)
  10. Ai J, "Safety and immunogenicity of SARS-CoV-2 vaccines in patients with chronic liver diseases(CHESS-NMCID 2101) : a multicenter study", Clin Gastroenterol Hepatol, 20, pp.1516~1524 (2022)
  11. Bakasis AD, "Antibody responses after SARS-CoV-2 vaccination in patients with liver diseases", Viruses, 14, pp.207~ (2022)
  12. Wang J, "Safety and immunogenicity of COVID-19 vaccination in patients with nonalcoholic fatty liver disease(CHESS2101) : a multicenter study", J Hepatol, 75, pp.439~441 (2021)
  13. Cornberg M, "EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients", J Hepatol, 74, pp.944~951 (2021)
  14. Chong PP, "A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients", Clin Ther, 39, pp.1581~1598 (2017)
  15. Ruether DF, "SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients", Clin Gastroenterol Hepatol, 20, pp.162~172 (2022)
  16. Cholankeril G, "Clinical factors associated with lack of serological response to SARS-CoV-2 messenger RNA vaccine in liver transplantation recipients", Liver Transpl, 28, pp.123~126 (2022)
  17. Holden IK, "Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients", J Intern Med, 290, pp.1264~1267 (2021)
  18. Huang HJ, "Early humoral immune response to two doses of severe acute respiratory syndrome coronavirus 2 vaccine in a diverse group of solid organ transplant candidates and recipients", Clin Transplant, 36, pp.e14600~ (2022)
  19. Marion O, "Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants", Ann Intern Med, 174, pp.1336~1338 (2021)
  20. Rabinowich L, "Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients", J Hepatol, 75, pp.435~438 (2021)
  21. Thuluvath PJ, "Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases", J Hepatol, 75, pp.1434~1439 (2021)
  22. Earle KA, "Evidence for antibody as a protective correlate for COVID-19 vaccines", Vaccine, 39, pp.4423~4428 (2021)
  23. Khoury DS, "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection", Nat Med, 27, pp.1205~1211 (2021)
  24. Bergwerk M, "Covid-19 breakthrough infections in vaccinated health care workers", N Engl J Med, 385, pp.1474~1484 (2021)
  25. Xiang T, "Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection", Cell Mol Immunol, 18, pp.2679~2681 (2021)
  26. He T, "Safety and antibody response to inactivated COVID-19 vaccine in patients with chronic hepatitis B virus infection", Liver Int, 42, pp.1287~1296 (2022)
  27. Zeng X, "The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline : a systematic review", J Evid Based Med, 8, pp.2~10 (2015)
  28. Deeks JJ, "Cochrane Handbook for systematic reviews of interventions", pp.241~284 (2019), Cochrane
  29. van Houwelingen HC, "Advanced methods in meta-analysis : multivariate approach and meta-regression", Stat Med, 21, pp.589~624 (2002)
  30. Sterne JA, "Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials", BMJ, 343, pp.d4002~ (2011)
  31. Kovalic AJ, "Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes : a systematic review and meta-analysis", Hepatol Int, 14, pp.612~620 (2020)
  32. Kim D, "Predictors of outcomes of COVID-19 in patients with chronic liver disease : US multi-center study", Clin Gastroenterol Hepatol, 19, pp.1469~1479 (2021)
  33. Alukal JJ, "Vaccination in chronic liver disease : an update", J Clin Exp Hepatol, 12, pp.937~947 (2022)
  34. Zost SJ, "Potently neutralizing and protective human antibodies against SARS-CoV-2", Nature, 584, pp.443~449 (2020)
  35. Hall VG, "Humoral and cellular immune response and safety of twodose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients", Am J Transplant, 21, pp.3980~3989 (2021)
  36. Herrera S, "Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients", Am J Transplant, 21, pp.3971~3979 (2021)
  37. Fernández-Ruiz M, "Discordance between SARS-CoV-2-specific cell-mediated and antibody responses elicited by mRNA-1273 vaccine in kidney and liver transplant recipients", Transplant Direct, 7, pp.e794~ (2021)
  38. Le Bert N, "SARS-CoV-2-specific T cell immunity in cases of COVID-19and SARS, and uninfected controls", Nature, 584, pp.457~462 (2020)
  39. Chen M, "Safety of SARS-CoV-2 vaccines : a systematic review and meta-analysis of randomized controlled trials", Infect Dis Poverty, 10, pp.94~ (2021)
  40. Fix OK, "American Association for the Study of Liver Diseases Expert Panel Consensus Statement : vaccines to prevent coronavirus disease 2019 infection in patients with liver disease", Hepatology, 74, pp.1049~1064 (2021)
  41. Schmidt T, "Immunogenicity and reactogenicity of heterologous ChAdOx1nCoV-19", mRNA vaccination, 2021, pp.27, 1530~1535
  42. Feng S, "Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection", Nat Med, 27, pp.2032~2040 (2021)
  43. Gilbert PB, "Immune correlates analysis of the mRNA-1273COVID-19 vaccine efficacy trial", medRxiv (2021)[DOI]
  44. Rashidi-Alavijeh J, "Humoral response to SARS-Cov-2 vaccination in liver transplant recipients-a single-center experience", Vaccines(Basel), 9, pp.738~ (2021)
  45. Boyarsky BJ, "Antibody response to 2-Dose SARS-CoV-2mRNA vaccine series in solid organ transplant recipients", JAMA, 325, pp.2204~2206 (2021)
  46. Davidov Y, "Immunogenicity and adverse effects of the 2-dose BNT162b2 messenger RNA vaccine among liver transplantation recipients", Liver Transpl, 28, pp.215~223 (2022)
  47. Erol Ç, "Differences in antibody responses between an inactivated SARS-CoV-2 vaccine and the BNT162b2 mRNA vaccine in solid-organ transplant recipients", Exp Clin Transplant, 19, pp.1334~1340 (2021)
  48. Guarino M, "Humoral response to 2-dose BNT162b2 mRNA COVID-19vaccination in liver transplant recipients", Clin Gastroenterol Hepatol, 20, pp.1534~1541 (2022)
  49. Mazzola A, "Poor antibody response after two doses of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)vaccine in transplant recipients", Clin Infect Dis, 74, pp.1093~1096 (2022)
  50. Midas B Mulder, "High antibody response in relation to immunosuppressive blood levels in liver transplant recipients after SARS-CoV-2 vaccination: an observational, cohort study", Gut, 71(12), pp.2605~2608 (2022), BMJ[DOI]
  51. Nazaruk P, "Unexpectedly high efficacy of SARSCoV-2 BNT162b2 vaccine in liver versus kidney transplant recipients-is it related to immunosuppression only?", Vaccines (Basel), 9, pp.1454~ (2021)
  52. Strauss AT, "Antibody response to severe acute respiratory syndrome-coronavirus-2 messenger RNA vaccines in liver transplant recipients", Liver Transpl, 27, pp.1852~1856 (2021)
  53. Timmermann L, "Humoral immune response following SARSCoV-2 vaccination in liver transplant recipients", Vaccines(Basel), 9, pp.1422~ (2021)

관련 논문AI추천

Antibody Response Induced by Two Doses of ChAdOx1 nCoV-19, mRNA-1273, or BNT162b2 in Liver Transplant Recipients김성한, 송기원, Kim Ji Yeun, Lee Sung-Gyu, Lim So Yun, Tak Eunyoung, Yoon Young-In대한면역학회 · Immune Network2022 · 제22권 제3호Reply to Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”Chiu Hang Mok, Ka Shing Cheung, Man Fung Yuen, Wai Kay Seto대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”Rujittika Mungmunpuntipantip, Viroj Wiwanitkit대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipientsIvan FN Hung, Ka Shing Cheung, Kwok Hung Chan, Lok Ka Lam, Man-Fung Yuen, Rex Wan Hin Hui, Ruiqi R Zhang, Wai Kay Seto, Xianhua Mao대한간학회 · Clinical and Molecular Hepatology2022 · 제28권 제3호SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and OutcomesBaldelli Luke, Barnes Eleanor, Barritt A. Sidney, Marjot Thomas, Moon Andrew M., Webb Gwilym J.거트앤리버 소화기연관학회협의회 · Gut and Liver2023 · 제17권 제1호The Seroconversion Rate of Hepatitis A Virus Vaccination among Patients with Hepatitis B Virus-Related Chronic Liver Disease in Korea김유진, Byung Chul Yoo, Hyun Chin Cho, Joon Hyeok Lee, Kwang Cheol Koh, Moon Seok Choi, Seung Woon Paik거트앤리버 소화기연관학회협의회 · Gut and Liver2011 · 제5권 제2호

이 간행물의 다른 논문 (24건)

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinomaNational Cancer Center (NCC) Korea, Korean Liver Cancer Association (KLCA)pp. 583-705The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathologyJong-Hoon Kim, Youngseok Leepp. 706-724Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative reviewGiovanni Targher, Ming-Hua Zheng, Jing Xu, Lei Miao, Christopher D Byrnepp. 725-738Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive reviewJong Man Kim, Sang Jin Kimpp. 739-753Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncologyHyun-Jong Jang, Sung Hak Leepp. 754-772
원문 보기